Glycopeptide antibiotics: back to the future
Mark S Butler1, Karl A Hansford1, Mark A T Blaskovich1
1Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Brisbane, Australia.
The Journal of Antibiotics
|August 14, 2014
Summary
Glycopeptide antibiotics like vancomycin combat Gram-positive infections. Newer lipoglycopeptides offer improved properties and broader activity against resistant bacteria, expanding treatment options.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Glycopeptide antibiotics, including vancomycin and teicoplanin, have been crucial for treating Gram-positive bacterial infections for decades.
- Increasing bacterial resistance necessitates the development of novel therapeutic agents.
- Semisynthetic lipoglycopeptides represent a significant advancement in glycopeptide antibiotic therapy.
Purpose of the Study:
- To review the discovery, development, and resistance patterns of established and novel glycopeptide antibiotics.
- To discuss the clinical implications of glycopeptide resistance, particularly to vancomycin.
- To explore future prospects for glycopeptide drugs and the development of new agents.
Main Methods:
- Literature review of glycopeptide antibiotics, focusing on vancomycin, teicoplanin, telavancin, dalbavancin, and oritavancin.
- Analysis of discovery, development timelines, and resistance mechanisms.
- Discussion of clinical efficacy, pharmacokinetic properties, and regulatory status.
Main Results:
- Vancomycin and teicoplanin remain important but face increasing resistance.
- Second-generation lipoglycopeptides (telavancin, dalbavancin, oritavancin) exhibit broader spectra and improved pharmacokinetics.
- Telavancin and dalbavancin are approved; oritavancin is pending regulatory approval.
Conclusions:
- Glycopeptide antibiotics continue to evolve, with newer agents addressing resistance challenges.
- Understanding resistance mechanisms is critical for effective clinical use and future drug development.
- Continued research into novel glycopeptides is essential to combat evolving bacterial threats.
Related Concept Videos
01:23Inhibitors of Gram-positive Cell Wall Synthesis
178
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
178
01:25Inhibitors of Bacterial Protein Synthesis
98
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
98
01:28Peptidoglycan Synthesis
4.7K
Structure of PeptidoglycanPeptidoglycan is a vital structural component of the bacterial cell wall, providing mechanical strength and shape to the cell. It consists of repeating units of two sugars—N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM)—linked by β-1,4 glycosidic bonds. These sugar chains are cross-linked by short peptide chains, forming a mesh-like polymer that surrounds the bacterial plasma membrane.Cytoplasmic Phase – Precursor SynthesisPeptidoglycan...
4.7K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Antimicrobial Proteins
10.6K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
10.6K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K